SOURCE: Mazal Plant Pharmaceuticals, Inc.

February 16, 2010 17:04 ET

Mazal Plant Pharmaceuticals, Inc. Completes Funding Term Sheet to Continue Development of MAHDL, Its IND HDL Therapy

NEW YORK, NY--(Marketwire - February 16, 2010) - Mazal Plant Pharmaceuticals, Inc. (FRANKFURT: M9J) announced today the completion of a term sheet for USD 324,000 in new funding over 18 months that will help advance Mazal and its development of MAHDL01, the company's Investigational New Drug for Cholesterol and HDL therapy.

The company has also created a new website to provide information to shareholders.

About Mazal Plant Pharmaceuticals, Inc.

Mazal Plant Pharmaceuticals, Inc. is an early-stage whole plant pharmaceutical development company whose mission is to develop treatments for chronic diseases from combinations of whole plants and to build shareholder value through negotiated relationships with strategic partners to fund commercialization and marketing of these treatments on a stand-alone or combination basis.

Mazal's lead candidate, MAHDL01, is a unique combination of whole plants that has shown a potential in early clinical studies to increase the HDL/LDL ratio. Controlled clinical studies have shown evidence that increasing this ratio in adults may improve overall cardiovascular health.

Mazal believes that MAHDL01 may also demonstrate an improved side effect profile due to its comprising natural components in contrast to commonly synthesized compounds.

Mazal is currently planning a Phase I/II, double-blind, placebo and active-controlled, randomized, parallel-group study to evaluate the safety and efficacy of MAHDL01 alone and as an adjunct to statin therapy, versus placebo or statin therapy alone, in increasing HDL in subjects with low HDL cholesterol who are maintaining a restricted diet.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Mazal Plant Pharmaceuticals, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Mazal Plant Pharmaceuticals's Inc subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Mazal Plant Pharmaceuticals assumes no responsibility to update the information included herein for events occurring after the date hereof.

For more information, please see :

Contact Information

    LC Group
    Rick Lutz
    (404) 261-1196